Many Women Willing to Extend Cervical Cancer Screening Intervals

Article

Women in routine gynecologic care expressed willingness to extend screening intervals and use cytology alone or Pap-HPV cotesting if recommended by a physician.

Cytological specimen showing cervical cancer

Cytological specimen showing cervical cancer

Women in routine gynecologic care expressed willingness to extend intervals between screening to a certain extent, and to use cytology alone or Pap-Human Papillomavirus (HPV) cotesting if recommended by a physician, according to a new survey.

In 2012 several professional organizations including the American Cancer Society, the American Society for Colposcopy and Cervical Cytology, and the American Society for Clinical Pathology changed their recommendations against annual screening. The US Preventive Services Task Force considered both cytology alone at 3-year intervals and HPV cotesting with cytology at 5-year intervals to be acceptable strategies for women between the ages of 30 and 65.

“HPV cotesting with a 3-year screening interval has been an acceptable option since 2003, yet uptake of cotesting in clinical practice has been slow,” wrote researchers led by Patti E. Gravitt, PhD, MS, of the University of New Mexico in Albuquerque. She and colleagues conducted a survey of 551 women aged 36 to 62 who were enrolled in the Human Papillomavirus in Perimenopause Study to assess attitudes toward new cervical cancer screening options. Results were published in the February issue of Obstetrics & Gynecology.

Most of the women (55.6%) were aware that screening recommendations had recently changed, though 74.1% believed that women should still be screened annually. If it came with a recommendation from their physician, 68.4% of women would accept extending that interval to every 3 years; only 25.2% would extent to 5 years, however.

Participants were also asked about screening test preference, and 60.7% said they preferred Pap tests only. Another 31.5% did not have a preference and were willing to be screened by Pap or HPV testing, and 7.8% preferred HPV testing alone. Many women (41.4%) said they would experience either moderate or severe anxiety if screened with an HPV test alone.

“A desire for more frequent care, higher anxiety, and higher perceived risk were all associated with being less willing to accept alternatives to annual Pap tests,” the researchers wrote. They noted that the study is limited by its non-representative population: these participants are older, of higher socioeconomic status, and are in routine screening.

In an accompanying editorial, George F. Sawaya, MD, and Miriam Kuppermann, PhD, both of the University of California, San Francisco, wrote that the fact that women would change practices if recommended shows the importance of providers in implementing evidence-based guidelines. “Additional discussion is warranted to define the appropriate role of patient preferences in screening decisions, specifically regarding screening interval,” they wrote.

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Despite the addition of a TIGIT inhibitor to a checkpoint inhibitor resulting in high levels of safety, there is no future for that combination alone, according to Ritu Salani, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Related Content